NVO - Novo Nordisk A/S
49.91 +0.41 (0.83%)
Pre-Market: 7:15AM EDT
| Previous Close | 49.67 |
| Open | 49.63 |
| Bid | 49.83 x 1100 |
| Ask | 49.95 x 1000 |
| Day's Range | 49.34 - 50.03 |
| 52 Week Range | 41.23 - 53.55 |
| Volume | 1,537,407 |
| Avg. Volume | 1,498,149 |
| Market Cap | 119.159B |
| Beta (3Y Monthly) | 0.64 |
| PE Ratio (TTM) | 20.11 |
| EPS (TTM) | 2.46 |
| Earnings Date | N/A |
| Forward Dividend & Yield | 1.25 (2.52%) |
| Ex-Dividend Date | 2019-03-22 |
| 1y Target Est | 57.90 |
- Yahoo Finance
Abbott, Sanofi to help diabetes patients with technology team-up
Abbott and Sanofi announce a new collaboration to help diabetes patients.
- Benzinga
The Week Ahead In Biotech: Novo Nordisk And Merck Await FDA Rulings, 2 IPOs On Deck
Biotech stocks rebounded in last week after declining modestly in the previous week. Some of the drugs that cleared the FDA hurdle this week include Ardelyx Inc (NASDAQ: ARDX )'s constipation drug Ibsrela; ...
CNW GroupNew international study: The hidden burden of diabetes on family members revealed
MISSISSAUGA, ON , Sept. 10, 2019 /CNW/ - People living with diabetes are not the only ones impacted by the condition. Low blood sugar or "lows" as they are often referred to by people living with diabetes, are a well-known side-effect of diabetes treatment, especially when using insulin, and they can be very unpleasant and dangerous if not managed properly.
- Reuters
UPDATE 1-Novo Nordisk to cut insulin prices in the U.S.
Novo Nordisk will offer cheaper insulin to U.S. diabetics, the Danish drugmaker said on Friday, in response to criticism over the high price of the medication and after similar moves by rivals Sanofi and Eli Lilly. President Donald Trump has made high prescription drug prices a top issue in the 2016 presidential campaign and said that drug companies were "getting away with murder". Novo will offer a generic version of its most heavily prescribed insulin drug Novolog, used by about a million U.S. patients, at a 50% discount compared to the current list price, the company said in a statement.
- Reuters
Novo Nordisk to cut insulin prices in the U.S.
Novo Nordisk will offer cheaper insulin to U.S. diabetics, the Danish drugmaker said on Friday, in response to criticism over the high price of the medication and after similar moves by rivals Sanofi and Eli Lilly. President Donald Trump has made high prescription drug prices a top issue in the 2016 presidential campaign and said that drug companies were "getting away with murder". Novo will offer a generic version of its most heavily prescribed insulin drug Novolog, used by about a million U.S. patients, at a 50% discount compared to the current list price, the company said in a statement.
- Motley Fool
2 Stocks to Watch in September
These two businesses could receive a big boost this month if certain events fall in their favor.
- Zacks
Vertex (VRTX) Inks All-Cash Deal to Acquire Semma for $950M
Vertex (VRTX) inks an all-cash deal to buy privately-held Semma Therapeutic. The acquisition will add pre-clinical type I diabetes candidates to its pipeline.
- Simply Wall St.
We Think Novo Nordisk (CPH:NOVO B) Can Stay On Top Of Its Debt
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
- American City Business Journals
Drugmaker's $27 million gift will have 'big impact' on NC State
The Novo Nordisk Foundation is investing big into bio-manufacturing research, and at the heart of their new $27 million investment is N.C. State University.
- Zacks
J&J (JNJ) Loses Landmark Opioid Case: What's Next for Pharmaceuticals?
An Oklahoma judge ruled on Monday that large cap pharmaceutical company Johnson & Johnson (JNJ) would have to pay $572 million to the state.
- Benzinga
Attention Biotech Investors: Mark Your Calendar For These September PDUFA Dates
FDA activity remained brisk in August. The FDA gave its nod for a majority of drugs that came up for review, although Vanda Pharmaceuticals Inc. (NASDAQ: VNDA )'s jet lag disorder drug Hetlioz and Sarepta ...
- Zacks
Gilead & Galapagos Close Research & Development Agreement
Gilead (GILD) closes collaboration agreement with Galapagos, per which the latter will receive an upfront license fee payment of $3.95 billion.
- Zacks
Novo Nordisk (NVO) Is Up 2.77% in One Week: What You Should Know
Does Novo Nordisk (NVO) have what it takes to be a top stock pick for momentum investors? Let's find out.
- InvestorPlace
Novo Nordisk Suing Mylan Over Generic Victoza Drug
News of Novo Nordisk suing Mylan is spreading as the two companies prepare for a legal battle.Source: joreks / Shutterstock.com The reason behind the upcoming legal battle has to do with Victoza. This is Novo Nordisk's (NYSE:NVO) drug for treating diabetes. Mylan (NASDAQ:MYL) is looking to market its own generic version of the drug, which is where the rub comes from.Novo Nordisk is seeking to block any efforts by Mylan to market its generic version of Victoza. Having a generic version of the drug available would eat into the revenue the company would make from selling its name brand version.InvestorPlace - Stock Market News, Stock Advice & Trading TipsNovo Nordisk is also seeking to protect its products that still have patent protection. The patents surrounding Victoza will start expiring in July 2021 and the last one will reach its expiration date in March 2033, reports BioSpace.Novo Nordisk suing Mylan specifically has to do with this new drug from the latter being an alleged illegal generic of its own. The company is filing this lawsuit in response to an abbreviated new drug application filed by Mylan with the U.S. Food & Drug Administration. * 10 Marijuana Stocks That Could See 100% Gains, If Not More The lawsuit from Novo Nordisk against Mylan was filed on Monday. This had the company filing its lawsuit with the U.S. District Court for the District of Delaware. Lawsuits can be lengthy procedures, so it will likely be some time before we see the outcome of this one.NVO stock was up 1% and MYL stock was down slightly as of Thursday afternoon. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Marijuana Stocks That Could See 100% Gains, If Not More * 11 Stocks Under $10 to Buy Now * 6 China Stocks to Buy on the Dip As of this writing, William White did not hold a position in any of the aforementioned securities.The post Novo Nordisk Suing Mylan Over Generic Victoza Drug appeared first on InvestorPlace.
- Zacks
Novo Nordisk's Fiasp Gets EC Approval for Label Expansion
Novo Nordisk (NVO) receives EC approval for its fast-acting insulin aspart, Fiasp, for the treatment of diabetes in adolescents and children aged one year or older.
- GuruFocus.com
5 Dividend Growth Stocks to Consider in Light of Falling Treasury Yields
High dividend yield stocks include 2 semiconductor manufacturers Continue reading...
- Zacks
The Zacks Analyst Blog Highlights: Cisco, Medtronic, Novo Nordisk, Southern and TransDigm
The Zacks Analyst Blog Highlights: Cisco, Medtronic, Novo Nordisk, Southern and TransDigm
- Zacks
Top Stock Reports for Cisco, Medtronic & Novo Nordisk
Top Stock Reports for Cisco, Medtronic & Novo Nordisk
- Reuters
UPDATE 2-Novo Nordisk contests Danish lawsuit claiming $1.75 bln
Danish insulin-maker Novo Nordisk said it would fight a lawsuit filed in a Danish court on Friday which alleges the company made misleading statements about its insulin business in the United States, the company said in a statement. "Novo Nordisk disagrees with the allegations and is prepared to defend the company in this matter," the company said. The securities lawsuit was filed by a number of shareholders who claims compensation worth a total of 11.785 billion Danish crowns ($1.75 billion) based on trading of Novo shares for two years from February 2015.
